News
HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Raises Price Target to $74
6 Mar 24
News, Price Target, Analyst Ratings
JP Morgan Maintains Overweight on SpringWorks Therapeutics, Raises Price Target to $74
6 Mar 24
News, Price Target, Analyst Ratings
Barclays Maintains Overweight on SpringWorks Therapeutics, Raises Price Target to $63
29 Feb 24
News, Price Target, Analyst Ratings
SpringWorks Therapeutics: Q4 Earnings Insights
27 Feb 24
Earnings
Wedbush Maintains Outperform on SpringWorks Therapeutics, Raises Price Target to $70
26 Feb 24
News, Price Target, Analyst Ratings
Barclays Maintains Overweight on SpringWorks Therapeutics, Raises Price Target to $47
25 Jan 24
News, Price Target, Analyst Ratings
Press releases
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
18 Apr 24
News, Press Releases
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
4 Mar 24
Health Care, Press Releases
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
29 Feb 24
Health Care, Press Releases, General
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
27 Feb 24
Earnings, Press Releases
Thinking about trading options or stock in Estee Lauder, Apple, Arista Networks, Walt Disney, or SpringWorks Therapeutics?
5 Feb 24
Small Cap, Opinion, Press Releases
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
31 Jan 24
News, Press Releases